CY1121822T1 - Βραδεια ενδοκοιλιακη χορηγηση - Google Patents
Βραδεια ενδοκοιλιακη χορηγησηInfo
- Publication number
- CY1121822T1 CY1121822T1 CY20181101209T CY181101209T CY1121822T1 CY 1121822 T1 CY1121822 T1 CY 1121822T1 CY 20181101209 T CY20181101209 T CY 20181101209T CY 181101209 T CY181101209 T CY 181101209T CY 1121822 T1 CY1121822 T1 CY 1121822T1
- Authority
- CY
- Cyprus
- Prior art keywords
- brain
- evening
- administration
- agents
- intraventricular administration
- Prior art date
Links
- 238000007914 intraventricular administration Methods 0.000 title abstract 2
- 210000004556 brain Anatomy 0.000 abstract 2
- 208000015439 Lysosomal storage disease Diseases 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 230000008499 blood brain barrier function Effects 0.000 abstract 1
- 210000001218 blood-brain barrier Anatomy 0.000 abstract 1
- 239000000032 diagnostic agent Substances 0.000 abstract 1
- 229940039227 diagnostic agent Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000003193 general anesthetic agent Substances 0.000 abstract 1
- 230000035515 penetration Effects 0.000 abstract 1
- 230000002093 peripheral effect Effects 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Psychology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Pulmonology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US77145106P | 2006-02-09 | 2006-02-09 | |
| PCT/US2007/003382 WO2007095056A2 (en) | 2006-02-09 | 2007-02-08 | Slow intraventricular delivery |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1121822T1 true CY1121822T1 (el) | 2020-07-31 |
Family
ID=38372004
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20181101209T CY1121822T1 (el) | 2006-02-09 | 2018-11-15 | Βραδεια ενδοκοιλιακη χορηγηση |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US20090123451A1 (https=) |
| EP (2) | EP1988823B1 (https=) |
| JP (4) | JP2009526066A (https=) |
| CN (1) | CN101404927A (https=) |
| AR (1) | AR059372A1 (https=) |
| BR (1) | BRPI0707900A2 (https=) |
| CA (2) | CA3168881C (https=) |
| CY (1) | CY1121822T1 (https=) |
| DK (1) | DK1988823T3 (https=) |
| ES (2) | ES2697502T3 (https=) |
| HU (1) | HUE040490T2 (https=) |
| IL (2) | IL193242A (https=) |
| LT (1) | LT1988823T (https=) |
| MX (4) | MX392030B (https=) |
| PL (1) | PL1988823T3 (https=) |
| PT (1) | PT1988823T (https=) |
| RU (1) | RU2452368C2 (https=) |
| SI (1) | SI1988823T1 (https=) |
| WO (1) | WO2007095056A2 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR059089A1 (es) * | 2006-01-20 | 2008-03-12 | Genzyme Corp | Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal |
| DK1988823T3 (en) * | 2006-02-09 | 2018-12-03 | Genzyme Corp | SLOW INTRAVENTRICULAR ADMINISTRATION |
| US20120322861A1 (en) | 2007-02-23 | 2012-12-20 | Barry John Byrne | Compositions and Methods for Treating Diseases |
| PL3252161T3 (pl) | 2007-06-06 | 2022-03-07 | Genzyme Corporation | Terapia genowa dla lizosomalnych chorób spichrzeniowych |
| EP2167071B1 (en) * | 2007-06-13 | 2020-03-18 | Wayne State University Board Of Governors | A baclofen solution for low-volume therapeutic delivery |
| CN102549152B (zh) | 2009-07-31 | 2015-11-25 | 帕克斯瓦克斯股份有限公司 | 基于腺病毒的载体 |
| SI3998078T1 (sl) | 2009-08-28 | 2026-02-27 | Genzyme Corporation | Encimsko nadomestno zdravljenje z naraščajočim odmerkom za zdravljenje pomanjkanja kisle sfingomielinaze |
| RS62620B1 (sr) | 2010-06-25 | 2021-12-31 | Shire Human Genetic Therapies | Metode i kompozicije za isporuku cns akrilsulfataze a |
| RS61055B1 (sr) | 2012-06-19 | 2020-12-31 | Univ Florida | Kompozicije i postupci za lečenje bolesti |
| CN105377039A (zh) * | 2013-05-15 | 2016-03-02 | 明尼苏达大学董事会 | 腺相关病毒介导的基因向中枢神经系统转移 |
| GB201508025D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Fabry disease gene therapy |
| TWI835747B (zh) | 2017-09-22 | 2024-03-21 | 賓州大學委員會 | 用於治療黏多醣病 ii 型之基因治療 |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| US20220193250A1 (en) | 2018-08-02 | 2022-06-23 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8303626D0 (sv) | 1983-06-23 | 1983-06-23 | Kabigen Ab | A recombinant plasmid a transformant microorganism, a polydoxyrebonucleotide segment, a process for producing a biologically active protein, and the protein thus produced |
| US5670488A (en) | 1992-12-03 | 1997-09-23 | Genzyme Corporation | Adenovirus vector for gene therapy |
| US5919676A (en) | 1993-06-24 | 1999-07-06 | Advec, Inc. | Adenoviral vector system comprising Cre-loxP recombination |
| AU7676894A (en) * | 1993-08-27 | 1995-03-21 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Convection-enhanced drug delivery |
| CA2189067A1 (en) | 1994-04-28 | 1995-11-09 | Gary J. Nabel | Gene delivery vector using plasmid dna packaged into an adenovirus and a packaging cell line |
| DE69628744D1 (de) | 1995-04-17 | 2003-07-24 | Univ Texas System Austin Board | Adenovirus helfervirus system |
| SI0833934T2 (sl) | 1995-06-15 | 2013-04-30 | Crucell Holland B.V. | Pakirni sistemi za humani rekombinantni adenovirus za uporabo v genski terapiji |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| CA2239366A1 (en) | 1996-01-05 | 1997-07-17 | Genetic Therapy, Inc. | Recombinase-mediated generation of adenoviral vectors |
| US5735814A (en) * | 1996-04-30 | 1998-04-07 | Medtronic, Inc. | Techniques of treating neurodegenerative disorders by brain infusion |
| JP4001925B2 (ja) | 1996-09-13 | 2007-10-31 | トランスカーヨティック セラピーズ インク． | α―ガラクトシダーゼＡ欠損症の治療 |
| US7033598B2 (en) * | 1996-11-19 | 2006-04-25 | Intrabrain International N.V. | Methods and apparatus for enhanced and controlled delivery of a biologically active agent into the central nervous system of a mammal |
| US6042579A (en) * | 1997-04-30 | 2000-03-28 | Medtronic, Inc. | Techniques for treating neurodegenerative disorders by infusion of nerve growth factors into the brain |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| WO1999057296A1 (en) | 1998-05-01 | 1999-11-11 | Genzyme Corporation | Partially deleted adenoviral vectors |
| US20060014166A1 (en) | 2004-01-27 | 2006-01-19 | Yossi Cohen | Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of endometriosis |
| US6702945B2 (en) | 2000-12-28 | 2004-03-09 | Exxonmobil Research And Engineering Company | Ionic membranes for organic sulfur separation from liquid hydrocarbon solutions |
| US6689756B2 (en) * | 2001-03-02 | 2004-02-10 | Integra Lifesciences Corporation | Treatment of neurological disease |
| AU2002357805A1 (en) * | 2001-12-07 | 2003-06-23 | Neuron Therapeutics | Protection of neurological tissue by direct cns perfusion cooling |
| US7923032B2 (en) * | 2002-11-26 | 2011-04-12 | Seacoast Neuroscience, Inc. | Buoyant polymer particles for delivery of therapeutic agents to the central nervous system |
| RU2253486C2 (ru) * | 2003-03-03 | 2005-06-10 | Ростовский научно-исследовательский онкологический институт МЗ РФ | Способ химиотерапии опухолей центральной нервной системы |
| CA2518407A1 (en) * | 2003-03-12 | 2004-09-23 | Samaritan Pharmaceuticals, Inc. | Animal model simulating neurologic disease |
| US20040258666A1 (en) | 2003-05-01 | 2004-12-23 | Passini Marco A. | Gene therapy for neurometabolic disorders |
| CA2525236C (en) * | 2003-06-20 | 2015-03-24 | Biomarin Pharmaceutical Inc. | Delivery of therapeutic compounds to the brain and other tissues |
| US20050026823A1 (en) * | 2003-06-20 | 2005-02-03 | Biomarin Pharmaceutical Inc. | Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues |
| US7442372B2 (en) * | 2003-08-29 | 2008-10-28 | Biomarin Pharmaceutical Inc. | Delivery of therapeutic compounds to the brain and other tissues |
| US20050208090A1 (en) * | 2004-03-18 | 2005-09-22 | Medtronic, Inc. | Methods and systems for treatment of neurological diseases of the central nervous system |
| US20080233655A1 (en) * | 2004-03-31 | 2008-09-25 | Children, Youth And Women's Health Service | Screening For Lysosomal Storage Disease Status |
| AR059089A1 (es) | 2006-01-20 | 2008-03-12 | Genzyme Corp | Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal |
| AR059088A1 (es) * | 2006-01-20 | 2008-03-12 | Genzyme Corp | Administracion intraventricular de una proteina para esclerosis lateral amiotrofica |
| DK1988823T3 (en) | 2006-02-09 | 2018-12-03 | Genzyme Corp | SLOW INTRAVENTRICULAR ADMINISTRATION |
| PL3252161T3 (pl) | 2007-06-06 | 2022-03-07 | Genzyme Corporation | Terapia genowa dla lizosomalnych chorób spichrzeniowych |
-
2007
- 2007-02-08 DK DK07750236.7T patent/DK1988823T3/en active
- 2007-02-08 EP EP07750236.7A patent/EP1988823B1/en active Active
- 2007-02-08 PT PT07750236T patent/PT1988823T/pt unknown
- 2007-02-08 AR ARP070100529A patent/AR059372A1/es not_active Application Discontinuation
- 2007-02-08 CA CA3168881A patent/CA3168881C/en active Active
- 2007-02-08 EP EP18188582.3A patent/EP3459441B1/en active Active
- 2007-02-08 PL PL07750236T patent/PL1988823T3/pl unknown
- 2007-02-08 WO PCT/US2007/003382 patent/WO2007095056A2/en not_active Ceased
- 2007-02-08 RU RU2008136196/14A patent/RU2452368C2/ru not_active IP Right Cessation
- 2007-02-08 SI SI200732069T patent/SI1988823T1/sl unknown
- 2007-02-08 MX MX2018015511A patent/MX392030B/es unknown
- 2007-02-08 MX MX2008010125A patent/MX358492B/es active IP Right Grant
- 2007-02-08 ES ES07750236T patent/ES2697502T3/es active Active
- 2007-02-08 LT LTEP07750236.7T patent/LT1988823T/lt unknown
- 2007-02-08 ES ES18188582T patent/ES3054134T3/es active Active
- 2007-02-08 CN CNA2007800098972A patent/CN101404927A/zh active Pending
- 2007-02-08 BR BRPI0707900-1A patent/BRPI0707900A2/pt not_active IP Right Cessation
- 2007-02-08 CA CA2641359A patent/CA2641359C/en active Active
- 2007-02-08 JP JP2008554340A patent/JP2009526066A/ja active Pending
- 2007-02-08 HU HUE07750236A patent/HUE040490T2/hu unknown
- 2007-02-08 MX MX2013013333A patent/MX361816B/es unknown
-
2008
- 2008-08-05 IL IL193242A patent/IL193242A/en not_active IP Right Cessation
- 2008-08-07 US US12/187,896 patent/US20090123451A1/en not_active Abandoned
- 2008-08-07 MX MX2022005303A patent/MX2022005303A/es unknown
-
2013
- 2013-08-21 JP JP2013171131A patent/JP6129685B2/ja active Active
-
2015
- 2015-09-25 JP JP2015188744A patent/JP6408970B2/ja active Active
-
2016
- 2016-10-25 IL IL248492A patent/IL248492A0/en unknown
-
2017
- 2017-08-08 JP JP2017152871A patent/JP6617125B2/ja active Active
-
2018
- 2018-11-15 CY CY20181101209T patent/CY1121822T1/el unknown
-
2019
- 2019-02-21 US US16/281,961 patent/US11253485B2/en active Active
-
2022
- 2022-01-10 US US17/572,330 patent/US20220370348A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1121822T1 (el) | Βραδεια ενδοκοιλιακη χορηγηση | |
| IL273765A (en) | Combinations and forms of administration of therapeutic agents and combined treatment | |
| IL171607A (en) | Use of botulinum toxin for the treatment of sinusitis-induced headaches | |
| ECSP056076A (es) | Sistema de suministro para droga y terapia celular | |
| EA200900155A1 (ru) | Модуляторы фармакокинетических свойств лекарственных средств | |
| CY1116464T1 (el) | Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης | |
| MX2010004510A (es) | Metodo para prevenir los efectos nocivos de peptido 1 tipo glucagon (glp-1). | |
| AR049985A1 (es) | Tratamiento de combinacion para enfermedades malignas no hematologicas | |
| BRPI0922789A2 (pt) | peptídeo de ligação de albumina intermediador para reconhecimento de doença | |
| TW200833367A (en) | Pharmaceutical compositions and method for treating inflammation in cattle and other animals | |
| EA200700214A1 (ru) | Мемантин в качестве дополнительной терапии к атипичным антипсихотическим средствам у больных шизофренией | |
| MX2008001520A (es) | Composiciones de tizanidina y metodos de tratamiento usando las composiciones. | |
| DE602005010844D1 (de) | Pharmazeutische zusammensetzungen mit interferon-tau | |
| RU2008129232A (ru) | Способ лечения туберкулеза легких у больных вич-инфекцией | |
| RU2006119263A (ru) | Способ лечения больных розацеа | |
| MX2009006670A (es) | Composicion farmaceutica que usa el aliskiren y el avosentan. | |
| RU2007141393A (ru) | Способ лечения спастического и болевого синдромов у пациентов с последствиями позвоночно-спинномозговой травмы | |
| MX2021007324A (es) | Terapia oral con acido 6,8-bis-benciltio-octanoico. | |
| AR061046A1 (es) | Mirtazapina para el tratamiento del dolor neuropatico | |
| RU2007138452A (ru) | Способ лечения пушных зверей при отодектозе | |
| RU2005106577A (ru) | Средство для лечения и профилактики острого панкреатита и способы его применения | |
| RU2005104368A (ru) | Способ лечения воспалительных заболеваний головного мозга | |
| RU2010143898A (ru) | Противоопухолевое средство, включающее производное цитидина и карбоплатин | |
| JP2008214331A (ja) | ピンポイント注射りょう法 | |
| RU2009145054A (ru) | Оксинтомодулин человека, его применение, лекарственный препарат на его основе и способ применения препарата для лечения и профилактики гипергликемии |